Integra LifeSciences(US:IART)2025-10-30 12:30Financial Performance - Q3 2025 revenue grew organically by 5% compared to Q3 2024[8, 9] - Adjusted EPS for Q3 2025 was $054, a 317% increase compared to $041 in Q3 2024[7, 10] - Adjusted EBITDA margin for Q3 2025 was 195%, a 330 bps increase compared to 162% in Q3 2024[10] - Q3 2025 operating cash flow was $409 million with a free cash flow conversion of 619%[11] Segment Performance - Codman Specialty Surgical (CSS) Q3 2025 revenue was $2926 million, with organic growth of 71% compared to Q3 2024[13] - Tissue Technologies Q3 2025 revenue was $1095 million, a 03% organic decrease compared to Q3 2024[17] Guidance and Outlook - Q4 2025 reported revenue is projected to be between $420 million and $440 million, with organic growth ranging from -59% to -14%[26] - Full year 2025 reported revenue is projected to be between $162 billion and $164 billion, with organic growth ranging from -16% to -04%[27, 28] - Full year 2025 adjusted EPS is projected to be between $219 and $224[28]